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Introduction 
The prevailing neurochemical theory about biological correlates 
of suicidal behavior focuses on the serotonergic system (Asberg 
et al 1987); however, several data are available about the 
implication of the noradrenergic system in the control of inward- 
directed aggression. In 1976, Beskow et al showed a decrease of 
norepinephrine levels in the putamen of suicide victims. Beta- 
adrenergic receptors have been found significantly increased, 
decreased, or unchanged in the frontal cortex of suicide victims 
(review in Little et al 1993). Recently, Meana et al (1992) 
reported an increased presynaptic alpha2-adrenergic receptor 
sensitivity in the brain of suicide victims. Secunda et al (1986) 
showed smaller urinary outputs of the norepinephrine metabolite 
3-methoxy-4-hydroxyphenylglycol (MHPG) and a lower plasma 
concentration of MHPG in suicide attempters compared to 
patients without history of suicidal behavior. Cerebrospinal fluid 
(CSF) studies have also provided additional data for the nor- 
adrenergic hypothesis of suicidal behavior but with controversy. 
Brown et al (1979) found higher levels of CSF MHPG in 
personality disorder patients with a history of suicide attempt 
than in controls. Agren (1980) reported a negative correlation 
between measures of suicidal tendencies and CSF MHPG levels 
in depressed patients. In 1993, Tr~iskman-Bendz et al showed an 
increase CSF MHPG in violent suicide attempters. More re- 
cently, we suggested an involvement of the noradrenergic sys- 
tem, particularly alpha2-adrenergic function, in the expression of 
suicidal behavior by demonstrating a smaller growth hormone 
(GH) response to clonidine, an alpha2-adrenergic agonist, in 
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depressed patients with a history of suicide attempts in compar- 
ison to nonattempters (Pitchot et al 1994). This study raised the 
hypothesis that a hyposensitivity of postsynaptic alpha2-adren- 
ergic receptors could be a determinant of suicidal behavior; 
however, this relationship between a blunted GH response to 
clonidine and suicidality could be observed in depressed patients 
only, but not in other diagnostic categories. In the present study, 
in order to test this hypothesis, GH responses to intravenous 
clonidine challenge were measured in nondepressed patients with 
a history of suicide attempts. 
Methods 
Subjects 
The study was performed in 18 nondepressed male patients with 
a score less than 12 on the 17-item Hamilton depression scale 
(Hamilton 1960). This score was mainly due to aspecific symp- 
toms such as psychic and somatic anxiety, insomnia, or somatic 
complaints. The DMS-III-R clinical diagnoses of the patients 
were personality disorder (3 cases), anxiety disorder (7 cases), 
and adjustment disorder (8 eases). The patients were subgrouped 
into suicide attempters (n = 7) and nonattempters (n = 11). The 
two groups did not differ in mean age or weight. The clonidine 
test was performed after a drug-free period of at least 2 weeks. 
Moreover, there was no significant difference in washout periods 
between the two groups. 
Past history of suicide attempt was based on interviews with 
the patients and their family members. All patients were free of 
medical illness as evidenced by history, medical examination, 
electrocardiogram, chest X-ray, electroencephalogram, and rou- 
tine laboratory tests. Patients with a basal systolic blood pressure 
less than 100 mmHG were excluded from the study. Moreover, 
to be included, patients had to present a basal (tO) GH level less 
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than 5 ng/ml before the pharmacological challenge (Ansseau et al 
1984). The exclusion of subjects with basal GH values > 5 ng/ml 
was recommended by Laakmann (1990) who demonstrated that 
"prestimulator" healthy volunteers responded significantly less 
to a noradrenergic challenge than healthy volunteers with low 
basal values. Finally, the protocol was approved by the Ethical 
Committee of the University of Liege Medical School, and all 
patients were fully informed of the study and gave their consent. 
Neuroendocrine Test Procedure 
The clonidine test was performed in all subjects at bedrest after 
an overnight fast. At 7 AM, an indwelling catheter was inserted in 
a forearm vein. Blood samples of 10 ml were collected at - 20 ,  
0, +20, 40, 60 and 120 minutes after injection at 8 AM of 
clonidine, 0.15 mg diluted in saline to obtain 20 mL intrave- 
nously in 10 minutes. 
GH was measured with a double antibody radioimmunoassay 
(Franchimont 1968), with intraassay and interassay coefficients 
of variation of, respectively, 13.3 ± 4.7% and 14.8 ± 9.6% and 
a detection limit of 0.2 ng/ml. 
Data analysis 
GH responses to clonidine were measured by GH peak values 
following injection. Analyses were performed using absolute GH 
values as well as differences related to basal (tO) levels (relative 
values). Since the correlations between absolute and relative 
values were very high (r > 0.98), only absolute values are 
reported here. Because GH responses to clonidine were not 
normally distributed, GH values were log-transformed. The 
responses of patients with and without a history of suicide 
attempts were compared by analysis of covariance (ANCOVA) 
for age. 
Results 
Mean GH peak responses to clonidine did not differ between 
suicide attempters and nonattempters: (mean -4- SD) for GH 
peak, 5.07 ± 6.0 ng/ml vs 9.0 + 9.2 ng/ml, F = 0.17, df = 3, 15, 
p = 0.69, and for the log GH peak values, F = 0.43, df = 3, 15, 
p = 0.53. On the basis of a defined cutoff value of 5 ng/ml, five 
patients in the group of suicide attempters and four in the group 
of nonattempters presented a blunted GH response (X 2 = 2.1, 
df = 1, p = 0.15). 
Discussion 
The results of the present study do not confirm a specific role for 
alpha2-adrenergic receptors in the control of suicidal behavior. 
Indeed, mean GH peak responses to clonidine did not exhibit any 
significant difference between nondepressed suicide attempters 
and nonattempters. Moreover, a blunted GH response to 
clonidine did not appear to be a reliable "biological marker" of 
suicidal behavior. 
Our results are at variance with previous studies showing a 
trend for a decrease of noradrenergic activity in depressed 
patients with a history of suicidal behavior. In 1982, Ostroff et al 
found a lower 24-hour urinary norepinephrine-to-epinephrine 
ratio in three depressive patients with a history of severe suicide 
attempts compared to depressed controls without history of 
suicidal behavior. Secunda et al (1986) reported low urinary and 
plasma MHPG measures in suicide attempters compared to 
controls. CSF MHPG levels exhibited a similar trend only in 
bipolar patients (Secunda et al 1986). More specifically, recently, 
we found a blunted GH response to clonidine in major depressed 
patients with a history of suicide attempts compared to nonat- 
tempters (Pitchot et al 1994). Trestman et al (1993) have also 
found a relationship between a reduced noradrenergic activity as 
assessed by GH responses to clonidine and self-directed aggres- 
siveness in major depression; however, the results of our study 
are in agreement with a study of Roy et al (1989) who did not 
find any relationship between CSF, urinary, and plasma indices 
of noradrenergic function and history of suicide attempt. More- 
over, recently, in a sample of 22 major depressed male inpatients 
with a history of suicide attempts compared to 22 age-matched 
nonattempters, we failed to replicate our initial observation of an 
association between a blunted GH response to clonidine and 
suicidality (Pitchot et al in press). 
In conclusion, noradrenergic disturbances, particularly at the 
level of alpha2-adrenergic receptors, seem to play a minor role in 
the biology of inward-directed aggression. In fact, suicidal 
behavior could be associated with a blunting of GH response to 
clonidine in depression only, and not in other psychiatric 
disorders. 
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